Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Phase of Trial: Phase III
Latest Information Update: 08 May 2018
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms CHIME 1
- Sponsors Supernus Pharmaceuticals
- 08 May 2018 According to a Supernus Pharmaceuticals media release, approximately 86% of enrollment in the study has been completed.
- 27 Feb 2018 According to a Supernus Pharmaceuticals media release, currently enrollment is approximately 80% complete and is expected to continue through mid-2018, with data anticipated by the first quarter of 2019.
- 18 Sep 2017 According to a Supernus Pharmaceuticals media release, Current enrollment is at approximately 64% and the company continue to expect enrollment through mid-2018.